Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 17 Jul 2024 03:11:33 +0200Fri, 05 Jul 2024 15:07:00 +0200Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, upadacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0237/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001741-pip01-14-m06Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, upadacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0237/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001741-pip01-14-m06Fri, 05 Jul 2024 15:07:00 +0200Human medicineHuman medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Date of authorisation: 16/12/2019, Revision: 19, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/rinvoqHuman medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Date of authorisation: 16/12/2019, Revision: 19, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/rinvoqFri, 24 May 2024 17:02:00 +0200Human medicineRinvoq : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-4760-en_1.pdfRinvoq : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-4760-en_1.pdfFri, 24 May 2024 17:01:00 +0200Human medicine